Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Key Points

• Structure Therapeutics reported a quarterly loss of $0.49 per share, missing the consensus estimate by $0.10.
• Shares rose to $53.14 in mid-day trading, while the stock remains well below its 52-week high of $94.90 and has a market capitalization of approximately $3.78 billion.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and an average price target of $110.91, despite some recent rating downgrades and target reductions.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR traded up $0.52 during mid-day trading on Friday, reaching $53.14. 329,459 shares of the company's stock were exchanged, compared to its average volume of 558,888. The company's 50-day moving average is $47.63 and its 200-day moving average is $54.19. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -53.14 and a beta of -1.43. Structure Therapeutics has a 52-week low of $15.86 and a 52-week high of $94.90.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wall Street Zen upgraded shares of Structure Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Structure Therapeutics in a research report on Friday, July 17th. HC Wainwright lowered their price objective on Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating on the stock in a research note on Thursday, June 11th. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research note on Friday. Finally, Citigroup reissued a "market outperform" rating on shares of Structure Therapeutics in a research report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $110.91.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. State of Wyoming acquired a new position in shares of Structure Therapeutics in the 2nd quarter worth approximately $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Structure Therapeutics in the fourth quarter valued at approximately $127,000. Cibc World Market Inc. acquired a new position in Structure Therapeutics during the fourth quarter worth $226,000. Stifel Financial Corp purchased a new position in shares of Structure Therapeutics during the fourth quarter worth $336,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Structure Therapeutics in the second quarter valued at $129,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source